Your browser doesn't support javascript.
loading
AI-driven discovery of blood xenobiotic biomarkers in neovascular age-related macular degeneration using iterative random forests.
Künzel, Steffen E; Frentzel, Dominik P; Flesch, Leonie T M; Knecht, Vitus A; Rübsam, Anne; Dreher, Felix; Schütte, Moritz; Dubrac, Alexandre; Lange, Bodo; Yaspo, Marie-Laure; Lehrach, Hans; Joussen, Antonia M; Zeitz, Oliver.
Afiliação
  • Künzel SE; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany. steffen-emil.kuenzel@charite.de.
  • Frentzel DP; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
  • Flesch LTM; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
  • Knecht VA; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
  • Rübsam A; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
  • Dreher F; Alacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
  • Schütte M; Alacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
  • Dubrac A; Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC, H3C 3J7, Canada.
  • Lange B; Alacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
  • Yaspo ML; Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195, Berlin, Germany.
  • Lehrach H; Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195, Berlin, Germany.
  • Joussen AM; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
  • Zeitz O; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Article em En | MEDLINE | ID: mdl-38842593
ABSTRACT

PURPOSE:

To investigate the xenobiotic profiles of patients with neovascular age-related macular degeneration (nAMD) undergoing anti-vascular endothelial growth factor (anti-VEGF) intravitreal therapy (IVT) to identify biomarkers indicative of clinical phenotypes through advanced AI methodologies.

METHODS:

In this cross-sectional observational study, we analyzed 156 peripheral blood xenobiotic features in a cohort of 46 nAMD patients stratified by choroidal neovascularization (CNV) control under anti-VEGF IVT. We employed Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for measurement and leveraged an AI-driven iterative Random Forests (iRF) approach for robust pattern recognition and feature selection, aligning molecular profiles with clinical phenotypes.

RESULTS:

AI-augmented iRF models effectively refined the metabolite spectrum by discarding non-predictive elements. Perfluorooctanesulfonate (PFOS) and Ethyl ß-glucopyranoside were identified as significant biomarkers through this process, associated with various clinically relevant phenotypes. Unlike single metabolite classes, drug metabolites were distinctly correlated with subretinal fluid presence.

CONCLUSIONS:

This study underscores the enhanced capability of AI, particularly iRF, in dissecting complex metabolomic data to elucidate the xenobiotic landscape of nAMD and environmental impact on the disease. The preliminary biomarkers discovered offer promising directions for personalized treatment strategies, although further validation in broader cohorts is essential for clinical application.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article